Clinical Trials | July 27, 2022
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Company raises the annual revenue guidance from mid-teens to high teens
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
Subscribe To Our Newsletter & Stay Updated
